SEC Comment Letter for Immunovant, Inc. (IMVT) (CIK 0001764013) (IMVT) — Feb 28, 2024

Immunovant, Inc. (IMVT) (CIK 0001764013)
Date: Feb. 28, 2024 · CIK: 0001764013 · Accession: 0000000000-24-002245

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-38906

Date

February 28, 2024

Author

Eva Renee Barnett

Form

UPLOAD

Company

Immunovant, Inc. (IMVT) (CIK 0001764013)

Letter

United States securities and exchange commission logo February 28, 2024 Eva Renee Barnett Chief Financial Officer Immunovant, Inc. 320 West 37th Street New York, NY 10018 Re:Immunovant, Inc. Form 10-K for the Fiscal Year Ended March 31, 2023 Filed May 22, 2023 File No. 001-38906 Dear Eva Renee Barnett: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text

United States securities and exchange commission logo
February 28, 2024
Eva Renee Barnett
Chief Financial Officer
Immunovant, Inc.
320 West 37th Street
New York, NY 10018
Re:Immunovant, Inc.
Form 10-K for the Fiscal Year Ended March 31, 2023
Filed May 22, 2023
File No. 001-38906
Dear Eva Renee Barnett:
            We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences

SecProbe.io